Results 111 to 120 of about 48,174 (231)

Оценка качества жизни при различных сердечно-сосудистых заболеваниях

Качественная клиническая практика, 2018
Различные заболевания влияют не только на физическое состояние человека, но и на психологию его поведения, эмоциональные реакции, а также изменяют его место и роль в социальной жизни. Чаще всего в поле зрения врача оказываются физикальные, лабораторные и

doaj  

The Use of QALYs in Clinical and Patient Decision-Making: Issues and Prospects

Качественная клиническая практика, 2018
.
Paul Kind, Jennifer Elston Lafata, Karl Matuszewski, Dennis Raisch, I. A. Vilum, A. S. Kolbin   +5 more
doaj  

ОЦЕНКА КЛИНИКО-ФАРМАКОЭКОНОМИЧЕСКОЙ ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕГО БАКТЕРИАЛЬНОГО ВАГИНОЗА

Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta
Введение. Рецидивирующий бактериальный вагиноз (БВ) ассоциирован с частыми повторными курсами терапии и значимой нагрузкой на бюджет здравоохранения.
Д. Э. Станько
doaj   +1 more source

Pharmacoeconomic analysis of use the oral hypoglycemic agents in patients with type 2 diabetes mellitus according to a real clinical practice

Качественная клиническая практика, 2018
We aimed to conduct cost-utility analysis of two different regimens of the oral hypoglycemic therapy in 2 type diabetes mellitus (DM2). Methods. In the whole, 229 patients with DM2, receiving vildagliptin add-on to metformin (group 1) or sulphonylureas ...
T. I. Ionova, T. P. Nikitina, A. Y. Rodionov, K. A. Kurbatova   +3 more
doaj  

Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review

PLoS ONE, 2022
Background Decision-making in healthcare policy involves assessing both costs and benefits. In determining the cost-effectiveness (CE) threshold, willingness to pay (WTP) per quality-adjusted life year (QALY), GDP per capita, and other factors are ...
Haru Iino, Masayuki Hashiguchi, Satoko Hori   +2 more
doaj  

Cost-utility plane and incremental cost-utility acceptability curve QALY.

, 2018
Cost-utility plane and incremental cost-utility acceptability curve QALY.
Irma H. J. Everink (4898452), Jolanda C. M. van Haastregt (4898449), Jos M. G. A. Schols (3228828), Silvia M. A. A. Evers (643477), Gertrudis I. J. M. Kempen (583581)   +4 more
core   +1 more source

The Oregon Plan and QALYs

AMA Journal of Ethics, 2005
A controversial Oregon plan used quality-of-life assessments to provide fewer health care services to a larger pool of Medicaid patients. Virtual Mentor is a monthly bioethics journal published by the American Medical Association.
openaire   +2 more sources

Sensitivity analysis results (LY: life year, QALY: quality adjusted life year, ICER: incremental cost effectiveness ratio); Simulation 1: Exacerbation rate = -46% and Increase QALY = 0.125; Simulation 2: Exacerbation rate = -46% and COPD costs = -10%, Simulation 3: Exacerbation rate = -46% and COPD costs = -10% and Increase QALY = 0.125.

, 2016
Sensitivity analysis results (LY: life year, QALY: quality adjusted life year, ICER: incremental cost effectiveness ratio); Simulation 1: Exacerbation rate = -46% and Increase QALY = 0.125; Simulation 2: Exacerbation rate = -46% and COPD costs = -10 ...
Kokuvi Atsou (205340), Perrine Crequit (3165123), Christos Chouaid (205344), Gilles Hejblum (205352)   +3 more
core   +1 more source

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review

ClinicoEconomics and Outcomes Research, 2020
Chakrapani Balijepalli,1 Lakshmi Gullapalli,1 Eric Druyts,1 Kevin Yan,1 Kamal Desai,1 Stephane Barakat,2 Jason Locklin2 1Pharmalytics Group, Vancouver, British Columbia, Canada; 2Alexion Pharmaceuticals, Vaughan, Ontario, CanadaCorrespondence: Chakrapani
Balijepalli C, Gullapalli L, Druyts E, Yan K, Desai K, Barakat S, Locklin J   +6 more
doaj  

Utility values (and associated probabilities) used to inform QALY values.

, 2018
Utility values (and associated probabilities) used to inform QALY values.
Brian Duggan (5680610), Andrew J. Sutton (813522), John V. Lamont (151190), Declan O’Rourke (692863), Gurdeep S. Sagoo (5680613), Cherith N. Reid (291365), Mark W. Ruddock (291368), Kate Williamson (5680607), R. Mark Evans (5680604)   +8 more
core   +1 more source